Search PubMed⌕ Search

Biomedical subjects

J Hamers

Publications and source records attributed to J Hamers.

At least 19 recordsLinked to original sources

Static, dynamic and first-pass MR imaging of musculoskeletal lesions using gadodiamide injection.

Forty-five patients with known or suspected musculoskeletal tumors were examined with static and dynamic MR imaging to evaluate the safety, tolerability and diagnostic utility of gadodiamide injection and to assess the diagnostic value of dynamic MR imaging and parametric "first-pass" (FP) images. The proportion of patients presenting more diagnostic information on the contrast-enhanced compared to the precontrast spin-echo examinations was determined. The dynamic enhancement characteristics were evaluated with time-intensity curves and parametric images of the FP enhancement rate. The tolerance of gadodiamide injection was good. Contrast enhancement was useful for delineating tumor from muscle, and differentiating viable from necrotic tissue and cystic from solid lesions. Malignant tumors showed a significantly higher slope value, earlier onset of enhancement, and higher maximum enhancement than benign lesions. However, slope values could not be used to predict the malignant potential of a lesion, due to overlap between highly vascular benign and low vascular malignant lesions. By displaying highly vascular areas, parametric FP images provided useful information on the most active part in a tumor before biopsy and for assessing the incorporation of bone-chip allografts. Static, dynamic and FP MR imaging using gadodiamide injection appears safe and provides useful information for diagnosis, biopsy and follow-up of musculoskeletal lesions.

Adult↗

Thallium-201 accumulation in myositis ossificans and in juxta-articular ossification.

We present the findings on 201Tl and 99mTc-MDP scintigraphy in three patients suffering from heterotopic ossification (two patients presenting with myositis ossificans and one patient presenting with juxta-articular ossification in combination with myositis ossificans). Since resection of the lesions has to be delayed until stabilization, 99mTc-MDP is often used as a parameter of lesional activity, although it is not optimal. For this clinical problem, we evaluated 201Tl scintigraphy as a marker of metabolic activity. In addition to the well-documented uptake of 99mTc-MDP, marked accumulation of 201Tl was observed in all heterotopic ossification sites. Hence, our results support the use of 201Tl scintigraphy in the therapeutic management and monitoring of conditions associated with ectopic ossification. On the other hand, although myositis ossificans is sometimes clinically, radiographically and even histologically confused with extraosseous osteogenic sarcoma, 201Tl accumulation may not be a helpful factor in the differential diagnosis due to the presence of tracer accumulation in both disorders.

Adult↗

Chylothorax after mantle field irradiation for Hodgkin's disease.

6 years after mantle field irradiation for stage IA Hodgkin's disease, a patient presented with right-sided chylothorax. Even after thorough investigation no etiology for the chylothorax was found. It is suggested that chylothorax can be due to previous radiotherapy.

Chylothorax↗

Mycosis fungoides and lymphoplasmacytoid immunocytoma in the same patient. A case report.

The simultaneous occurrence of two different lymphomas in a 57-year-old white woman is reported: mycosis fungoides and a leukemic lymphoplasmacytoid immunocytoma. The first was confirmed by histologic study and electron microscopy, and the latter by histologic study and immunoperoxidase staining. The lymphoid cells in the involved bone marrow and peripheral blood expressed the same surface immunoglobulin as was found in the cytoplasm of the immunocytoma cells, i.e., IgM-lambda. The clonal B-cell expansion was brought into a lasting remission by chlorambucil, but the cutaneous lymphoma proved to be refractory to therapy. The patient died 38 months after diagnosis.

Chlorambucil↗

Cytostatic therapy-induced vomiting inhibited by domperidone. A double-blind cross-over study.

A cross-over double-blind trial was conducted in 14 patients (20 double-blind treatment courses) comparing domperidone and placebo in the treatment of vomiting due to intensive cytostatic treatment. Eight ml, containing 16 mg of domperidone or placebo was injected one hour before the start of cytostatic therapy. The efficacy of the drug was evaluated by the investigator and the duration of nausea and vomiting was registered in the majority of the patients. Domperidone was preferred to placebo 13 times, whereas the reverse preference occurred only twice. The duration of both nausea (a median of 11 hours against seven hours) and vomiting (a median of 7 1/2 hours against 6 hours) was shorter with domperidone than with the placebo.

Adolescent↗